ArticleFrontiers in immunology2013
Thioredoxin ameliorates cutaneous inflammation by regulating the epithelial production and release of pro-inflammatory cytokines.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- The Role of Thioredoxin in Mitigating Ammonia-Induced Oxidative Stress in Nile Tilapia (Animals : an open access journal from MDPI · 2026Article
- Time to Occurrence of Incontinence-Associated Dermatitis: An Experimental Animal Study.Journal of inflammation research · 2025Article
- Thioredoxin: an antioxidant, a therapeutic target and a possible biomarker.Pediatric research · 2024Article
- Significant role and the underly mechanism of cullin-1 in chronic obstructive pulmonary disease.Open medicine (Warsaw, Poland) · 2024Article
- Geranylgeranylacetone Ameliorates Skin Inflammation by Regulating and Inducing Thioredoxin via the Thioredoxin Redox System.Antioxidants (Basel, Switzerland) · 2023Article
- Group AScience immunology · 2023Article
- Pharmacological therapy for stable chronic obstructive pulmonary disease.Chronic diseases and translational medicine · 2023Review
- Peptide-Protected Gold Nanoclusters Efficiently Ameliorate Acute Contact Dermatitis and Psoriasis via Repressing the TNF-α/NF-κB/IL-17A Axis in Keratinocytes.Nanomaterials (Basel, Switzerland) · 2023Article
- Shedding a New Light on Skin Aging, Iron- and Redox-Homeostasis and Emerging Natural Antioxidants.Antioxidants (Basel, Switzerland) · 2022Review
- Thioredoxin-1: A Promising Target for the Treatment of Allergic Diseases.Frontiers in immunology · 2022Review
- Progress in the mechanism and targeted drug therapy for COPD.Signal transduction and targeted therapy · 2020Review
- Attenuation of Hyperoxic Lung Injury in Newborn Thioredoxin-1-Overexpressing Mice through the Suppression of Proinflammatory Cytokine mRNA Expression.Biomedicines · 2020Article
- Well-aging: A new strategy for skin homeostasis under multi-stressed conditions.Journal of cosmetic dermatology · 2020Article
- Anti-Inflammatory Thioredoxin Family Proteins for Medicare, Healthcare and Aging Care.Nutrients · 2017Review
- Multifunctional Thioredoxin-Like Protein from the Gastrointestinal Parasitic NematodesJournal of parasitology research · 2016Article
- The role of NRF2 transcription factor in inflammatory skin diseases.BioFactors (Oxford, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human thioredoxin-1 (TRX) is a 12-kDa protein with redox-active dithiol in the active site -Cys-Gly-Pro-Cys-. It has been demonstrated that systemic administration and transgenic overexpression of TRX ameliorate inflammation in various animal models, but its anti-inflammatory mechanism is not well characterized. We investigated the anti-inflammatory effects of topically applied recombinant human TRX (rhTRX) in a murine irritant contact dermatitis (ICD) induced by croton oil. Topically applied rhTRX was distributed only in the skin tissues under both non-inflammatory and inflammatory conditions, and significantly suppressed the inflammatory response by inhibiting the production of cytokines and chemokines, such as TNF-α, Il-1β, IL-6, CXCL-1, and MCP-1. In an in vitro study, rhTRX also significantly inhibited the formation of cytokines and chemokines produced by keratinocytes after exposure to croton oil and phorbol 12-myristate 13-acetate. These results indicate that TRX prevents skin inflammation via the inhibition of local formation of inflammatory cytokines and chemokines. As a promising new approach, local application of TRX may be useful for the treatment of various skin and mucosal inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.